Open AccessA case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge
Author(s) -
Emin Taşkıran,
Sevnaz Şahin,
Sumru Savaş,
Zeliha Fulden Saraç,
Selahattin Fehmi Akçiçek
Publication year - 2021
Publication title -
international journal of immunotherapy and cancer research
Language(s) - English
Resource type - Journals
ISSN - 2455-8591
DOI - 10.17352/2455-8591.000033
Subject(s) - denosumab , medicine , osteoporosis , vitamin d and neurology , hyperparathyroidism , subcutaneous injection , differential diagnosis , urology , pathology
Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.